National Cancer Institute

Clinical Trials and Translational Research Advisory Committee's (CTAC) Role and Function

James L. Abbruzzese, M.D.

March 3, 2011

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute

CTAC Charter: Description of Duties

- The Committee makes recommendations on the NCI-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trials process.

http://deainfo.nci.nih.gov/advisory/ctac/ctacchr.pdf

National Cancer Institute

CTAC Charter: Description of Duties

- In addition, the Committee makes recommendations regarding the effectiveness of NCI's translational research management and administration program, including needs and opportunities across disease sites, patient populations, translational developmental pathways, and the range of molecular mechanisms responsible for cancer development.

National Cancer Institute

Function One – as of January 2007

- Provide extramural oversight of the implementation of the CTWG/TRWG recommendations and initiatives
  - Oversight of new NCI clinical trials informatics infrastructure

National Cancer Institute

Function Two – as of January 2007

- Provide strategic advice regarding NCI's entire clinical trials portfolio including resources associated with clinical trials
  - Assessment of the funding distribution for clinical trials across the NCI
  - Review of disease-specific clinical trials portfolios across the Institute

National Cancer Institute

Function Three – as of January 2007

- Advise on the use of new correlative science and quality of life funds

National Cancer Institute

Function Four – as of January 2007

- Develop recommendations for additional refinements to the NCI-supported clinical trials system based on analyses conducted as part of the implementation of the CTWG plan
  - Clinical trials operational efficiency of Cooperative Groups, Cancer Centers, and CTEP
  - Financial Analysis of phase III trial costs
  - Central IRB function

National Cancer Institute

Function Five – as of January 2007

- Provide a forum for the clinical trials community to give advice directly to the NCI Director
  - Only new NCI advisory committee in more than a decade
  - Dedicated exclusively to clinical trials
  - Broadly represents all stakeholders in the clinical trials enterprise